These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

218 related items for PubMed ID: 23907769

  • 21. G-CSF + plerixafor versus G-CSF alone mobilized hematopoietic stem cells in patients with multiple myeloma and lymphoma: a systematic review and meta-analysis.
    Li Y, Qiu X, Lei Y, Zhou R.
    Ann Med; 2024 Dec; 56(1):2329140. PubMed ID: 38470973
    [Abstract] [Full Text] [Related]

  • 22. [Effectiveness of plerixafor in patients undergoing mobilization autologous haematopoietic progenitor cell].
    Ruano Camps R, Ortiz Pareja M, Vidales Mancha I, Muñoz Castillo IM, Heiniger Mazo AI.
    Farm Hosp; 2013 Dec; 37(4):317-21. PubMed ID: 24010693
    [Abstract] [Full Text] [Related]

  • 23. Plerixafor: a peripheral blood stem cell mobilizer.
    Kessans MR, Gatesman ML, Kockler DR.
    Pharmacotherapy; 2010 May; 30(5):485-92. PubMed ID: 20411999
    [Abstract] [Full Text] [Related]

  • 24. Plerixafor and Filgrastim XM02 (Tevagastrim) as a first line peripheral blood stem cell mobilisation strategy in patients with multiple myeloma and lymphoma candidated to autologous bone marrow transplantation.
    Andreola G, Babic A, Rabascio C, Negri M, Martinelli G, Laszlo D.
    Eur J Haematol; 2012 Feb; 88(2):154-8. PubMed ID: 21992403
    [Abstract] [Full Text] [Related]

  • 25. Plerixafor injection: a hematopoietic stem cell mobilizer in non-Hodgkin lymphoma and multiple myeloma.
    Jantunen E, Varmavuo V, Valtola J.
    Expert Rev Hematol; 2016 Aug; 9(8):723-32. PubMed ID: 27355397
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. A prospective, multicenter study on hematopoietic stemcell mobilization with cyclophosphamide plus granulocyte colony-stimulating factor and 'on-demand' plerixafor in multiple myeloma patients treated with novel agents.
    Mina R, Petrucci MT, Bonello F, Bongarzoni V, Saccardi R, Bertuglia G, Mengarelli A, Spadaro A, Lisi C, Curci P, Lemoli RM, Ballanti S, Floris R, Cupelli L, Tosi P, Olivieri A, Rota-Scalabrini D, Cangialosi C, Nozzoli C, Anaclerico B, Fazio F, Bruno B, Mancuso K, Corradini P, Milone G, Boccadoro M.
    Haematologica; 2024 May 01; 109(5):1525-1534. PubMed ID: 37981892
    [Abstract] [Full Text] [Related]

  • 31. Plerixafor plus granulocyte colony-stimulating factor improves the mobilization of hematopoietic stem cells in patients with non-Hodgkin lymphoma and low circulating peripheral blood CD34+ cells.
    Maziarz RT, Nademanee AP, Micallef IN, Stiff PJ, Calandra G, Angell J, Dipersio JF, Bolwell BJ.
    Biol Blood Marrow Transplant; 2013 Apr 01; 19(4):670-5. PubMed ID: 23333777
    [Abstract] [Full Text] [Related]

  • 32. Safety and preliminary efficacy of plerixafor (Mozobil) in combination with chemotherapy and G-CSF: an open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin's lymphoma undergoing stem cell mobilization.
    Dugan MJ, Maziarz RT, Bensinger WI, Nademanee A, Liesveld J, Badel K, Dehner C, Gibney C, Bridger G, Calandra G.
    Bone Marrow Transplant; 2010 Jan 01; 45(1):39-47. PubMed ID: 19483760
    [Abstract] [Full Text] [Related]

  • 33. Plerixafor for stem cell mobilization in patients with non-Hodgkin's lymphoma and multiple myeloma.
    Choi HY, Yong CS, Yoo BK.
    Ann Pharmacother; 2010 Jan 01; 44(1):117-26. PubMed ID: 20009003
    [Abstract] [Full Text] [Related]

  • 34. Comparable efficacy and lower cost of PBSC mobilization with intermediate-dose cyclophosphamide and G-CSF compared with plerixafor and G-CSF in patients with multiple myeloma treated with novel therapies.
    Awan F, Kochuparambil ST, Falconer DE, Cumpston A, Leadmon S, Watkins K, Deremer D, Jillella A, Craig M, Hamadani M.
    Bone Marrow Transplant; 2013 Oct 01; 48(10):1279-84. PubMed ID: 23584435
    [Abstract] [Full Text] [Related]

  • 35. Plerixafor Plus Granulocyte Colony-Stimulating Factor for Patients with Non-Hodgkin Lymphoma and Multiple Myeloma: Long-Term Follow-Up Report.
    Micallef IN, Stiff PJ, Nademanee AP, Maziarz RT, Horwitz ME, Stadtmauer EA, Kaufman JL, McCarty JM, Vargo R, Cheverton PD, Struijs M, Bolwell B, DiPersio JF.
    Biol Blood Marrow Transplant; 2018 Jun 01; 24(6):1187-1195. PubMed ID: 29410180
    [Abstract] [Full Text] [Related]

  • 36. Effectiveness and cost analysis of "just-in-time" salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics.
    Li J, Hamilton E, Vaughn L, Graiser M, Renfroe H, Lechowicz MJ, Langston A, Prichard JM, Anderson D, Gleason C, Lonial S, Flowers CR, Kaufman JL, Waller EK.
    Transfusion; 2011 Oct 01; 51(10):2175-82. PubMed ID: 21492180
    [Abstract] [Full Text] [Related]

  • 37. Just-in-time rescue plerixafor in combination with chemotherapy and granulocyte-colony stimulating factor for peripheral blood progenitor cell mobilization.
    Smith VR, Popat U, Ciurea S, Nieto Y, Anderlini P, Rondon G, Alousi A, Qazilbash M, Kebriaei P, Khouri I, de Lima M, Champlin R, Hosing C.
    Am J Hematol; 2013 Sep 01; 88(9):754-7. PubMed ID: 23749720
    [Abstract] [Full Text] [Related]

  • 38. A comparison of chemo-free strategy with G-CSF plus plerixafor on demand versus intermediate-dose cyclophosphamide and G-CSF as PBSC mobilization in newly diagnosed multiple myeloma patients: An Italian explorative cost Analysis.
    Laszlo D, Marcacci GP, Martino M, Radice D, Rabascio C, Lucchetti B, Magarò A, Caime A, Menna S, Lionetti MT, Bertolini F.
    Transfus Apher Sci; 2020 Oct 01; 59(5):102819. PubMed ID: 32499108
    [Abstract] [Full Text] [Related]

  • 39. Plerixafor: a review of its use in stem-cell mobilization in patients with lymphoma or multiple myeloma.
    Keating GM.
    Drugs; 2011 Aug 20; 71(12):1623-47. PubMed ID: 21861545
    [Abstract] [Full Text] [Related]

  • 40. Peripheral blood CD34+ cell monitoring after cyclophosphamide and granulocyte-colony-stimulating factor: an algorithm for the pre-emptive use of plerixafor.
    Farina L, Spina F, Guidetti A, Longoni P, Ravagnani F, Dodero A, Montefusco V, Carlo-Stella C, Corradini P.
    Leuk Lymphoma; 2014 Feb 20; 55(2):331-6. PubMed ID: 23656194
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.